Company / Shareholders' Equity
Fulcrum Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$349.0M
FY2025
5-year range
$198.9M / $349.0M
FY2021-FY2025
Trend
+43.6%
vs FY2024
Sector context
#118 of 213
Health Care
What the data says
At $349M, Fulcrum Therapeutics, Inc.'s shareholders' equity ranks #118 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $199M in FY2022 to $349M in FY2025.
Based on SEC 10-K filings.
$349M in FY2025 with a 5-year CAGR of +29.7%.
Improved from $235M to $349M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +20.6%
- 5-Year CAGR
- +29.7%
- 10-Year CAGR
- -
Sector benchmark
#118 of 213 in Health CareTop 55% of 213This company $349.0M Sector average $2.5B
▼
-86.3% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +29.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 43.6% year-over-year.
- Ranks #118 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $349.0M | +43.6% |
| FY2024 | $243.0M | +3.3% |
| FY2023 | $235.2M | +18.2% |
| FY2022 | $198.9M | -6.0% |
| FY2021 | $211.5M | +122.2% |
| FY2020 | $95.2M | +9.2% |
| FY2019 | $87.2M | +236.9% |
| FY2018 | -$63.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026